REGENERON PHARMACEUTICALS, INC.

REGN 10-Q · Q1 2026
API behind this page

REGN Q1 2026 request

Playground key active
Request URL /api/financials?ticker=REGN&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 3,605.4 3,028.7 +19.0%
Show Product Lines breakouts
Collaboration revenue 1,899.7 1,531.2 +24.1%
Evkeeza · US 45.7 30.9 +47.9%
EYLEA HD And EYLEA · US 941.5 1,042.8 -9.7%
EYLEA HD · US 468.4 306.8 +52.7%
EYLEA · US 473.1 736 -35.7%
Libtayo 438.2 285.1 +53.7%
Libtayo · Non Us 152.1 92.6 +64.3%
Libtayo · US 286.1 192.5 +48.6%
Lynozyfic 11.2 — —
Other products 31.3 — —
Praluent · US 66.6 56.8 +17.3%
Product 1,534.5 1,415.6 +8.4%
Product And Service Other 171.2 81.9 +109.0%
Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses · Sanofi Collaboration Agreement, Antibody -16.7 -15.5 -7.7%
Regeneron's share of profits · Non Us 240 317.3 -24.4%
Regeneron's share of profits · Sanofi Collaboration Agreement, Antibody 1,450.8 1,018.2 +42.5%
Reimbursement for manufacturing of commercial supplies · Non Us 47.3 26.6 +77.8%
Reimbursement for manufacturing of commercial supplies · Sanofi Collaboration Agreement, Antibody 154.3 165 -6.5%
Reimbursement of commercialization-related expenses · Sanofi Collaboration Agreement, Antibody 184.1 159.2 +15.6%
Reimbursement of R&D expenses, net of Regeneron's obligation for its share of Bayer R&D expenses · Non Us 1 -9.4 +110.6%
Research & Development 1,543.5 1,327.4 +16.3%
Show Business Segments breakouts
Reportable Segment 1,543.5 1,327.4 +16.3%
Reportable Segment · Clinical manufacturing costs 364.1 310.3 +17.3%
Reportable Segment · Direct research and development expenses 498.6 388.4 +28.4%
Reportable Segment · Indirect research and development expenses: 59.3 60 -1.2%
Reportable Segment · Indirect research and development expenses: 170.9 154.4 +10.7%
Reportable Segment · Indirect research and development expenses: 484.2 451.6 +7.2%
Reportable Segment · Indirect research and development expenses: 714.4 666 +7.3%
Acquired In Process Research And Development 101.9 12.3 +728.5%
Selling, General & Administrative 647.7 633 +2.3%
Cost of Revenue (Q) — — —
Show Product Lines breakouts
Cost of collaboration and contract manufacturing 296 198.8 +48.9%
Product 373.4 265.5 +40.6%
Total Costs & Expenses 2,962.5 2,437 +21.6%
Operating Income 642.9 591.7 +8.7%
Other Non-Operating Income (Expense) 201.2 322 -37.5%
Interest Expense -12.9 -8.7 -48.3%
Non-Operating Income (Expense) 188.3 313.3 -39.9%
Income Before Taxes 831.2 905 -8.2%
Income Tax Expense (Benefit) 104 96.3 +8.0%
Net Income 727.2 808.7 -10.1%
Show Equity Components breakouts
Retained Earnings 727.2 808.7 -10.1%
EPS (Basic) 6.99 7.58 -7.8%
EPS (Diluted) 6.75 7.27 -7.2%
Wtd Avg Shares (Basic) 104 106.7 -2.5%
Wtd Avg Shares (Diluted) 107.7 111.2 -3.1%
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax -65.8 38.1 -272.7%
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent 0.2 -1.1 +118.2%
Comprehensive Income 661.6 845.7 -21.8%
Other Comprehensive Income -65.6 37 -277.3%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -65.6 37 -277.3%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 2,962.6 3,090.2 -4.1%
Marketable Securities (Current) 5,791.1 5,259.2 +10.1%
Accounts Receivable 5,731 5,561 +3.1%
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts
Trade Accounts Receivable 3.53 3.76 -6.1%
Show Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project breakouts
Bayer 241.1 373.2 -35.4%
Sanofi Collaboration Agreement, Antibody 1,713.2 1,192.8 +43.6%
Inventory 3,103.6 3,192.4 -2.8%
Prepaid Expenses & Other Current Assets 620.9 468.9 +32.4%
Total Current Assets 18,209.2 17,571.7 +3.6%
Non-Current Assets
Marketable Securities (Non-Current) 9,786 9,276.3 +5.5%
Deferred Tax Assets 4,190.9 3,442.9 +21.7%
Other Non-Current Assets 2,129.7 1,393.1 +52.9%
Total Assets 40,868.8 37,545.2 +8.9%
Other Assets
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization 5,266.1 4,694.2 +12.2%
Intangible Assets Net Excluding Goodwill 1,286.9 1,167 +10.3%
Current Liabilities
Accounts Payable 1,027.1 705.5 +45.6%
Accrued Liabilities And Other Liabilities 2,724.4 2,241.8 +21.5%
Finance Lease Liability Current 720 — —
Deferred Revenue (Current) 636.2 619.3 +2.7%
Total Current Liabilities 5,107.7 3,566.6 +43.2%
Non-Current Liabilities
Long-Term Debt 1,986.2 — —
Contract With Customer Liability Noncurrent 225.1 211.8 +6.3%
Other Non-Current Liabilities 2,126.2 1,674.4 +27.0%
Total Liabilities 9,445.2 8,157.6 +15.8%
Stockholders' Equity
Common Stock (Q) — — —
Show Statement Class Of Stock breakouts
Common Stock 0.1 0.1 0.0%
Additional Paid-In Capital 14,401.3 13,192.1 +9.2%
Retained Earnings 36,423.8 32,384.4 +12.5%
Accumulated Other Comprehensive Income 11.9 29.1 -59.1%
Treasury Stock Common Value -19,413.5 -16,218.1 -19.7%
Total Stockholders' Equity 31,423.6 29,387.6 +6.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 11.9 29.1 -59.1%
Additional Paid In Capital 14,401.3 13,192.1 +9.2%
Common Stock 0.1 0.1 0.0%
Retained Earnings 36,423.8 32,384.4 +12.5%
Treasury Stock Common -19,413.5 -16,218.1 -19.7%
Total Liabilities & Equity 40,868.8 37,545.2 +8.9%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation & Amortization 123.2 126.9 -2.9%
Stock-Based Compensation 257.4 255.7 +0.7%
Marketable And Other Securities Gain Loss -25 -139.9 +82.1%
Other Non-Cash Items 55.6 3.2 +1637.5%
Increase Decrease In Deferred Income Taxes -96 -139.1 +31.0%
Change in Accounts Receivable 1.2 657.8 -99.8%
Change in Inventory 26.6 -152.3 +117.5%
Change in Prepaid & Other Assets -198.6 -179.5 -10.6%
Change in Deferred Revenue 99.6 17.7 +462.7%
Increase Decrease In Accounts Payable And Accrued Liabilities 107.7 -214.1 +150.3%
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities 351.7 236.4 +48.8%
Net Cash from Operations 1,078.9 1,045.1 +3.2%
Investing Activities
Payments To Acquire Marketable Securities -2,755.9 -2,539.3 -8.5%
Proceeds From Sale And Maturity Of Marketable Securities 2,606.5 3,458.3 -24.6%
Payments To Acquire Productive Assets -230.6 -229.3 -0.6%
Payments To Acquire Intangible Assets1 -48.9 -42.2 -15.9%
Net Cash from Investing -428.9 647.5 -166.2%
Financing Activities
Proceeds From Issuance Of Common Stock 163.1 60.6 +169.1%
Tax Withholding for Share Compensation -73.2 -4.3 -1602.3%
Share Repurchases -794.3 -1,041.4 +23.7%
Payments Of Dividends -97.8 -93.8 -4.3%
Net Cash from Financing -802.2 -1,089.2 +26.3%
Supplemental
Unpaid Capital Expenditures 162.5 105.9 +53.4%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -0.9 0.6 -250.0%
Net Change in Cash -153.1 604 -125.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 2,970.6 3,093 -4.0%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key